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Objective: To study the ability of two strains of vancomycin-resistant Enterococcus faecium to colonize the human 
intestine. 
Methods: A single human subject ingested separately two strains of vancomycin-resistant E. faecium isolated from a 
pig and a chicken. The feces were cultured on selective medium. Prior to ingestion no vancomycin-resistant cocci were 
present in the feces. Ingestion of 104-105 CFU resulted in  either no colonization or isolation only after enrichment. 
Ingestion of lo7 CFU of one strain resulted in colonization for a period of nearly 3 weeks, with fecal counts a t  times in 
excess of lo6 CFU/g. Ingestion of similar numbers of the other strain and reingestion of the first strain resulted in 
excretion in the feces for much shorter periods. When the fecal count of the ingested strains was greater than 104-105 
CFU/g, the strains were isolated from swabs taken from perianal skin. 
Conclusions: Vancomycin-resistant E. faecium strains from pigs and poultry are able to colonize the human gut and 
the perianal skin. 
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INTRODUCTION 
The glycopeptide antibiotic vancomycin is used exten- 
sively to treat human infections with Eritevococcirs farcirrrn 
and methicillin-resistant Staphylococcus uirrrirs (MRSA) 
[l].This and the related antibiotic teicoplanin are two 
of the few antibiotics to which these organisms are 
sensitive. 
A related glycopeptide, avoparcin, has been in use 
in animal nutrition for many years as a growth- 
promoting feed additive. It was developed for use after 
chemotherapeutic antibiotics were banned from use as 
growth promoters in animals under UK and, later, 
European legislation [?I. However, at that time glyco- 
peptides were not used in human medicine. The 
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increasing use of vancomycin for treatment of hunian 
infections with niultiresistant Gram-positive bacteria 
has led to increasing concern over the size of the 
reservoir of vancomycin-resistant enterococci, particu- 
larly Biterococcnsfarciurn, in poultry and pigs, which has 
arisen, it is thought, largely as a result of the extensive 
use of avoparcin in animal nutrition [3-5]. Despite the 
extensive use in hospitals, which must also lead to 
selection for resistance, this problem has been addressed 
by the European Union, with the result that avoparcin 
has been withdrawn from use as a growth promoter on 
a temporary basis until more information has been 
acquired on whether or not it poses a public-health 
risk. Resistance is mediated through a conjugative 
transposon, T n  1516, which has been shown experi- 
mentally to be capable of transmitting between E. 
jiecalis and Staphylococcus airreus on the skin of mice [6]. 
Entry of poultry and pig strains into the human food 
chain could therefore pose a risk to public health as 
a result of the strains becoming established in the gut 
or transmitting resistance to other bacteria, such as 
staphylococci, in the gut or on the skin [ 1,7]. However, 
the ability of enterococci, derived from poultry or pigs, 
to colonize the human gut had not been proved and it 
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was very difficult to assess fully the size of the risk that 
the presence of these organisms in food animals posed 
It was considered that one way to determine 
whether E. fuerium strains of animal origin could 
colonize the human gut was to ingest cultures. A 
limited study to test this idea was carried out by the 
author and is described in this paper. 
PI. 
MATERIALS AND METHODS 
Bacteria 
Strains of E.  @ecium, showing high-level resistance to 
the glycopeptides vancomycin and avoparcin, mediated 
by Tn1.516, were obtained from F. Aarestrup, Danish 
Veterinary Laboratory, Copenhagen, Denmark. Two 
were chosen for use. They were E.-faecirtm 538 isolated 
from a chicken and E.  faeririm 539 isolated from a pig. 
Cultures were made in 10-mL volumes of Luria- 
Bertani broth (Difco) and incubated for 24 h at 37°C 
in a shaking incubator. They contained approximately 
1 x lo9 CFU/mL. They grew well on LB agar con- 
taining 100 mg/L vancomycin (Sigma), whereas fecal 
streptococci isolated from the author did not grow in 
the presence of this concentration of vancomycin. 
Inoculation procedure 
No food was taken by the single human subject for 
12 h prior to self-inoculation, which took place in the 
morning. A 24-h LB broth culture of the strain to be 
ingested was diluted in sterile distilled water to the 
required CFU density. Immediately after ingestion of 
10 or 20 mL of this suspension, 500 mL of sterile water 
was consumed. 
Bacterial enumeration 
Feces were collected aseptically in the morning, and 
perianal skin swabs were taken later in the day. Fecal 
samples were diluted 10-fold in LB broth, and further 
decimal dilutions in phosphate-buffered saline were 
plated on Mitis-Salivarius (MS) agar (Difco) without 
the potassium tellurite but containing either vanco- 
mycin (10 mg/L) and sodium nalidixate (20 mg/L) or 
sodium nalidixate alone. The first decimal dilution was 
also mixed with an equal volume of LB broth contain- 
ing vancomycin and sodium nalidixate at  twice the 
concentration present in the plates, and this culture was 
incubated overnight at 37OC before plating for single 
colonies on the antibiotic-containing MS agar. 
The tips of swabs taken from the skin were broken 
off aseptically into LB broth containing single-strength 
vancomycin and sodmm nalidxate, incubated overnight 
and plated on the MS agar with and without the 
antibiotics. 
RESULTS 
The viable counts of bacteria per gram of feces cultured 
on MS agar with sodium nalidixate and with and 
without vancomycin during the course of the experi- 
ment are shown in Figure 1. For 11 days prior to 
inoculation, the viable count fluctuated between (loglo) 
6.38 and 8.30 CFU per gram. All the dominant 
colonies were Gram-positive cocci but they were not 
identified further. A large mucoid colony generally 
formed between 1% and 50% of the total count. No 
vancomycin-resistant organisms were detected by direct 
plating (limit of sensitivity of loglo 1.0) or by enrich- 
ment during this period (Figure la).  
After lo5 CFU of E.faecilrrn 538 were ingested, no 
isolations of this organism were made. After the same 
number of E. faecium 539 CFUs were ingested, the 
organism was isolated once, and only by enrichment 
(Figure la). Ingestion of 10’ CFU ofstrain 538 resulted 
in isolation of this organism in the feces continuously 
for 20 days, with this strain at times forming between 
20% and 30% of the flora cultured on the MS agar 
(Figure lb). Towards the end of the third week the 
numbers of the strain fell, and it was eliminated quite 
abruptly, with only one isolation by enrichment. 
After 5 days, 10’ CFU of E.  faecium 539 were 
ingested. This strain was detected in the feces for only 
4 days. Since there seemed no reason why this strain 
should not be excreted for the same length of time as 
strain 538, 10’ CFU of strain 538 were again ingested 
8 days later. This strain was also eliminated from the gut 
after a much shorter period and was isolated for only 4 
days (Figure lc). Throughout the whole experiment 
the subject remained perfectly healthy. 
Twenty-nine perianal swabs were enriched and 
plated on MS agar without vancomycin. Growth was 
obtained on every occasion. Twenty-three swabs were 
taken during the periods when vancomycin-resistant 
strains were present in the feces, and after enrichment 
growth was obtained on MS agar containing vanco- 
mycin from 14 of them. When the fecal count of 
the ingested strains exceeded lo4 CFU/g, isolations 
were made on 13 of 14 occasions, but when the fecal 
count was less than this, the isolation rate fell to 1/9. 
DISCUSSION 
Although only one individual was studied, the short 
experiments reported on here demonstrate that vanco- 
mycin-resistant E. fueciurn strains originating from 
poultry and pig sources will colonize the human gut 
quite well. After ingestion of lo5 CFU of either strain, 
only one isolation was made, and then only by enrich- 
ment. Ingestion was in the early morning before food 
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Figure 1. Fecal excretion of vancomycin-resistant E. j w i u r n  strains by a hunian subject. Log10 viable counts (CFU) of cocci 
per gram feces isolated on Mitis-Salivarius (MS) agar containing sodium nalidixate (31 nig/L) and vancornycin (10 mg/L) 
(0) or sodium nalidixate alone ( W )  at days indicated after the start of the experiment. 1 indicates the day of ingestion of a 
particular strain together with the number of CFUs ingested. ( f )  indicates isolation of the vancomycin-retistant strain by 
enrichment only. Isolation of vancoinycin-sensitive or -resistant cocci from perianal skin gwabs incubated overnight in 
vanconiycin-sodium nalidixate broth, subcultured on MS agar (MS) or MS agar containing vancomycin (MS + VAN) 
respectively is indicated by a + or - at the bottom of each panel. 
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was consumed, but overnight starvation followed by 
little food consumption in the early morning is quite 
normal for many people. Ingestion of lo7 CFU of the 
two strains resulted in the isolation of considerable 
numbers of the ingested organism from the feces. It 
seems likely that the infectious dose for the author was 
slightly in excess of lo5 CFU. However, this may not 
necessarily reflect the infectious dose in food material, 
where foods rich in fat may protect bacteria from 
gastric acid. Enterococci (typical non-mucoid cocci 
isolated on MS agar) were readily isolated from the 
perianal skin throughout the experiment. Use of more 
appropriate enrichment broths might have increased 
the frequency of recovery. When the ingested strains 
were present in the feces at levels of lo4 CFU/g or 
more they were also nearly always isolated from the 
skin. This suggests that some poultry and pig strains will 
not only colonize the gut of at least some human beings 
but will come into direct contact with other skin 
bacteria, presumably including staphylococci. There is 
considerable concern over the possibility of transfer of 
Tn  1546, conferring resistance to glycopeptides such 
as vancomycin, teicoplanin and avoparcin, from vanco- 
mycin-resistant enterococci to MRSA in or outside a 
hospital environment [1,5]. There must obviously also 
be concern that the transfer demonstrated experi- 
mentally by Noble et a1 [6] might occur on the skin 
around the anus if vancomycin-resistant enterococci 
are present in the gut. 
The Swann recommendations of 1969 [3] were 
that chemotherapeutic antibiotics should not also be 
used for growth stimulation of food animals. Because 
of the potential risks associated with the use of 
avoparcin in pigs and poultry, which also include the 
exacerbation of fecal excretion of Salmoriella [9], the 
European Commission has withdrawn this antibiotic 
from use as a growth promoter, and the situation will 
be reviewed in 1998. The evidence provided in this 
paper will be available to the reviewing body at this 
time. Presumably, it will still be possible to use avoparcin 
therapeutically. There is considerable anecdotal evidence 
that it is effective against clostridial infections, and 
evidence of the susceptibility of Clostridiurn pevfviingeizs 
has been documented [9]. Prophylaxis must not, how- 
ever, be used to justify further overuse. 
One interesting observation from the present 
exercise was that, following the initial colonization of 
strain 538, infection with strain 539 or reinfection with 
strain 538 led to much reduced excretion. There are a 
number of possible explanations for this, including 
dietary factors. However, no  major changes in diet 
were undertaken by the author during the course of the 
experiment, and the numbers and major components 
of the coccal flora identified by eye were reasonably 
stable. Another possibility, therefore, was that an 
immune response was generated which shortened the 
duration of excretion of the strains inoculated later. 
This is potentially very exciting and would be worth- 
while pursuing further. If this is the case, it raises the 
possibility not only of human vaccination but also of 
protection of food animals by the same mechanism. 
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